Kare Schultz

Generic drugmaker Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported a first-quarter earnings beat as the company managed to maintain business continuity, CEO Kare Schultz said on CNBC's "Squawk on the Street." Teva's 'Very Good' Quarter Teva is dedicated to...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced a restructuring program late last year that is now showing some signs of early success, according to Credit Suisse. The Analyst Credit Suisse's Vamil Divan upgraded Teva's stock rating from Neutral to Outperform with a...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced Thursday a plan to eliminate more than 25 percent of its worldwide workforce as part of a strategy to slash $3 billion of annual costs. The Analyst Goldman Sachs' Jami Rubin upgraded Teva's stock from Neutral to Buy with...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s third quarter earnings report disappointed investors, as it included another reduction to its full year 2017 earnings per share and revenue outlook. The Analyst JPMorgan's Chris Schott downgraded Teva's stock rating from Neutral...

Analysts at Deutsche Bank see a scenario in which Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock can move higher from its current levels but are simultaneously no longer recommending investors be buying the stock. The firm's Gregg Gilbert downgraded Teva's stock from Buy...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) shareholders have had an extremely volatile couple of months. After an August guidance and dividend cut sent the stock tumbling from a July high of $33.67 to a September low of $15.22, Teva shares popped to above $20 when the company announced...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)’s having a big week, and it’s only Tuesday. The drug manufacturer’s stock popped as much as 24 percent Monday after the board appointed Kåre Schultz, current head of H. Lundbeck A/S and former COO of Novo Nordisk A/S (ADR...

Kare Schultz, a veteran pharmaceutical executive with a background in restructuring, was a big hit with investors after the 56-year-old Dane was chosen as CEO of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA), the world's biggest seller of generic medicines. Shares were up 20 percent on...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) shareholders are jumping for joy on Monday after the market gave new CEO Kare Schultz a warm welcome in the form of a 21 percent gain for Teva stock. However, once the euphoria of a new CEO wears off, traders should be looking for the reality of...

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) were trading higher by more than 11 percent early Monday morning after the company named Kare Schultz as its new CEO after a seven-month search period. Schultz brings decades of experience in the pharmaceutical industry and most...